Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
The prognosis of locally advanced esophageal squamous cell carcinoma is poor,the role of
chemotherapy as neoadjuvant therapy in locally advanced esophageal cancer has been
established, which can convert some unresectable esophageal cancer into resectable esophageal
cancer.PD-1 antibody has been shown to improve the pathological complete response rate in
NSCLC, however, the data in neoadjuvant of esophageal squamous carcinoma is relatively rare.
This study was designed to know the value of PD-1 antibody in neoadjuvant therapy of
esophageal cancer.